about
The putative cancer stem cell marker USP22 is a subunit of the human SAGA complex required for activated transcription and cell-cycle progressionUnsupervised clustering of gene expression data points at hypoxia as possible trigger for metabolic syndrome.Gene expression profiling of non-small-cell lung cancer.Lipocalin2 expressions correlate significantly with tumor differentiation in epithelial ovarian cancerNormalization using weighted negative second order exponential error functions (NeONORM) provides robustness against asymmetries in comparative transcriptome profiles and avoids false calls.Overexpression of glucose transporter-1 (GLUT-1) predicts poor prognosis in epithelial ovarian cancer.Antisense RNA transcripts in the blood may be novel diagnostic markers for colorectal cancer.
P2860
Q24307439-3333A55C-9420-4806-9B87-DAA8186323ACQ30478807-5027E930-4EC1-41AD-B20C-5DA37440D51DQ37118980-73D207FA-87C0-4895-83DE-8F992E189D29Q37174014-F5CCF106-AA41-49ED-B9C9-DE049CBF8752Q37318160-F5E1135D-E1A7-45F6-9582-DCDBF526144DQ39069754-E48906AA-F7D3-4220-9C8F-66BA814C1FC2Q41620607-12FFED0B-7E92-4AA7-98D8-CC7A2D1CB12F
P2860
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Impact of microarray technology in clinical oncology.
@ast
Impact of microarray technology in clinical oncology.
@en
type
label
Impact of microarray technology in clinical oncology.
@ast
Impact of microarray technology in clinical oncology.
@en
prefLabel
Impact of microarray technology in clinical oncology.
@ast
Impact of microarray technology in clinical oncology.
@en
P2860
P356
P1433
P1476
Impact of microarray technology in clinical oncology.
@en
P2093
Elizabeth A Raetz
Philip J Moos
P2860
P304
P356
10.1081/CNV-120030219
P577
2004-01-01T00:00:00Z